Hi — I'm Alma
Hi — I'm Alma. I put this guide together for you because navigating the world of neurology clinical trials can feel overwhelming, especially when you or someone you love is dealing with a condition like Parkinson's disease or Alzheimer's disease.
I'm not a doctor, and this isn't medical advice. Think of me more like a knowledgeable friend who's spent a lot of time organizing information about clinical research — so you don't have to start from scratch. My goal is to help you understand what's out there, what's actually being studied right now in the United States, and how to figure out whether a clinical trial might be worth exploring for your situation.
Let's walk through it together.
What Are Neurological Conditions Like Parkinson's and Alzheimer's?
Neurology is the branch of medicine that deals with disorders of the nervous system — your brain, spinal cord, and the network of nerves that runs through your entire body. When something goes wrong in this system, it can affect how you move, think, remember, speak, or even sleep.
Two of the most common and heavily researched neurological conditions are Parkinson's disease and Alzheimer's disease. They're different diseases, but they share something in common: both involve the gradual loss of nerve cells in the brain, and both can profoundly change a person's daily life.
Parkinson's disease primarily affects movement. It happens when neurons in a part of the brain called the substantia nigra start to break down or die. These neurons produce dopamine, a chemical messenger that helps coordinate smooth, purposeful movement. When dopamine levels drop, you may notice tremors (often starting in a hand), stiffness in the limbs or trunk, slowness of movement, and difficulty with balance. Over time, Parkinson's can also affect mood, sleep, thinking, and other non-motor functions. It's estimated that nearly one million people in the US live with Parkinson's, and that number continues to grow.
Alzheimer's disease is the most common cause of dementia — a general term for memory loss and other cognitive difficulties serious enough to interfere with everyday life. In Alzheimer's, abnormal protein deposits (amyloid plaques and tau tangles) build up in the brain, leading to the death of nerve cells. Early symptoms usually involve difficulty remembering recent events or conversations. As the disease progresses, it can affect language, reasoning, judgment, and the ability to carry out familiar tasks. Alzheimer's touches not just the person diagnosed but the entire circle of family and caregivers around them.
Both of these conditions are progressive, meaning they tend to get worse over time. Current treatments can help manage symptoms, but there are no cures yet — which is exactly why research is so important. Clinical trials are where new ideas about prevention, diagnosis, and treatment get tested in real people, and they represent some of the most hopeful frontiers in neurology today.
You may also see related terms come up in trial descriptions, like mild cognitive impairment, dementia, essential tremor, multiple system atrophy, or multiple sclerosis. These are all part of the broader landscape of neurological research.
What's Happening in Neurology Research Right Now
Right now, we're tracking 96 clinical trials in neurology across the United States on Alma — and the range of what's being studied is genuinely exciting.
The two biggest areas of focus are exactly what you'd expect: Parkinson's disease and Alzheimer's disease, which together account for the vast majority of studies in our curated list. But researchers aren't just looking at these conditions through a single lens. The trials span everything from new drug therapies and brain stimulation techniques to cognitive training programs, sleep research, biomarker exploration, and even studies on caregiver support.
In terms of trial phases, the landscape is diverse. There are 14 Phase 1 studies — these are early-stage trials that focus on safety and how the body responds to new interventions. We have 13 Phase 2 trials testing whether promising approaches actually work, 7 Phase 3 trials evaluating treatments in larger groups to confirm effectiveness, and 4 Phase 4 studies looking at drugs or interventions already approved to better understand long-term effects or new applications. A large number of studies (58) are observational or don't have a traditional drug-testing phase — these are often focused on understanding disease mechanisms, identifying biomarkers, or testing behavioral and technological interventions.
Some of the leading institutions driving this research include the University of Minnesota, which sponsors the most trials in our dataset with six studies, followed by the University of Florida, Washington University School of Medicine, and Brigham and Women's Hospital. The Mayo Clinic is exploring topics like brain stimulation for insomnia in Parkinson's patients and the effects of endocrine disruption on Alzheimer's. Vanderbilt University Medical Center is investigating autonomic failure and blood pressure medications like midodrine and droxidopa in people with conditions including Parkinson's and multiple system atrophy. The pharmaceutical company Hoffmann-La Roche also has two trials in our dataset, reflecting ongoing industry investment in neurological drug development.
What stands out across the board is how broad the approach has become. Researchers are studying neuroinflammation through microglial activation PET imaging (Brigham and Women's Hospital), looking at the role of sleep in Alzheimer's pathology (University of Massachusetts, Amherst), investigating glutathione and brain metabolism (Baylor College of Medicine), and testing cognitive training programs to reduce the incidence of cognitive impairment (University of South Florida). There's also meaningful attention being paid to real-world quality of life — studies on hearing aid outcomes in people with Alzheimer's dementia (Northwestern University) and research into culturally inclusive decision-making for families navigating dementia (Emory University).
This is a field in motion, and new trials are opening regularly.
What This Means for You as a Patient
If you're living with Parkinson's disease, Alzheimer's disease, or a related neurological condition — or if you're a caregiver — you might be wondering: Is a clinical trial right for me?
There's no single answer, because it depends entirely on your situation. But here's what I'd encourage you to consider:
- Clinical trials aren't a last resort. Some trials are for people in the earliest stages of a condition, or even for people at risk who haven't developed symptoms yet. Others are for people who've tried standard treatments without the results they hoped for. There's a wide range.
- You don't have to commit blindly. Every legitimate trial has a detailed informed consent process. You'll learn exactly what the study involves — the potential benefits, the risks, the time commitment — before you agree to anything.
- Your current doctor stays in the loop. Participating in a trial doesn't mean abandoning your existing care. In most cases, trial teams work alongside your regular physician.
Some questions worth asking if you're exploring a trial:
- What phase is this study in, and what does that mean for me?
- What are the possible side effects?
- Will I definitely receive the treatment, or is there a chance I'll be in a placebo group?
- How often will I need to visit the study site, and where is it?
- What happens when the trial ends?
You deserve clear answers to every one of those questions. And if something doesn't feel right, it's always okay to say no — or to take more time.
How Our Triage Works
At Alma, we built a guided chat experience to help you figure out which clinical trials you might be eligible for — without having to read through dozens of study listings on your own.
Here's how it works: you visit our neurology triage page, and Alma (that's me, in chat form) will ask you a few straightforward questions — things like your diagnosis, where you're located, and what kind of study you might be interested in. Based on your answers, I'll match you with relevant trials from our curated database.
No account required. No cost. No pressure. The process takes just a few minutes, and at the end you'll have a clear, personalized list of studies that might be a fit — along with next steps for reaching out to each trial's research team.
It's designed to be a starting point, not a final destination. You can always bring what you find to your doctor and talk it through together.
Ready to Explore Your Options?
If you're curious about what neurology clinical trials might be available for you or someone you care about, the simplest thing to do is start the conversation.
Start the triage here → almastudies.com/neurology
I'll walk you through it step by step. No jargon, no rush — just clear information to help you make the best decision for your situation.